Complement factor H and the hemolytic uremic syndrome

JP Atkinson, THJ Goodship - The Journal of experimental medicine, 2007 - rupress.org
JP Atkinson, THJ Goodship
The Journal of experimental medicine, 2007rupress.org
Immune recognition is coupled to powerful proinflammatory effector pathways that must be
tightly regulated. The ancient alternative pathway of complement activation is one such
proinflammatory pathway. Genetic susceptibility factors have been identified in both
regulators and activating components of the alternative pathway that are associated with
thrombotic microangiopathies, glomerulonephritides, and chronic conditions featuring debris
deposition. These observations indicate that excessive alternative pathway activation …
Immune recognition is coupled to powerful proinflammatory effector pathways that must be tightly regulated. The ancient alternative pathway of complement activation is one such proinflammatory pathway. Genetic susceptibility factors have been identified in both regulators and activating components of the alternative pathway that are associated with thrombotic microangiopathies, glomerulonephritides, and chronic conditions featuring debris deposition. These observations indicate that excessive alternative pathway activation promotes thrombosis in the microvasculature and tissue damage during debris accumulation. Intriguingly, distinct genetic changes in factor H (FH), a key regulator of the alternative pathway, are associated with hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (dense deposit disease), or age-related macular degeneration (AMD). A mouse model of HUS designed to mirror human mutations in FH has now been developed, providing new understanding of the molecular pathogenesis of complement-related endothelial disorders.
rupress.org